This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BPMC Blueprint Medicines (BPMC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Blueprint Medicines Stock (NASDAQ:BPMC) 30 days 90 days 365 days Advanced Chart Get Blueprint Medicines alerts:Sign Up Key Stats Today's Range$129.46▼$129.4650-Day Range$127.95▼$129.4852-Week Range$73.04▼$129.65VolumeN/AAverage Volume1.55 million shsMarket Capitalization$8.36 billionP/E RatioN/ADividend YieldN/APrice Target$130.00Consensus RatingHold Company Overview Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Read More Receive BPMC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BPMC Stock News HeadlinesShareholder Alert: The Ademi Firm Investigates the Blueprint Medicines Corporation TransactionAugust 27, 2025 | businesswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Blueprint Medicines Corporation (NASDAQ: BPMC)July 14, 2025 | globenewswire.comWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's latest plans for the dollar – and they're so bold that one central bank chair says we haven't seen anything like it in almost a century. Our Wall Street insider says it's the start of a once-in-a-lifetime investing opportunity, IF you act now.September 7 at 2:00 AM | Stansberry Research (Ad)BPMC Blueprint Medicines Corporation - Seeking AlphaJuly 1, 2025 | seekingalpha.comBlueprint Medicines Corporation (BPMC) - Yahoo FinanceJune 29, 2025 | finance.yahoo.comBlueprint Medicines Presents Strong Long-Term Data for AYVAKIT in Systemic MastocytosisJune 24, 2025 | msn.comBLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint ...June 22, 2025 | morningstar.comMBLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMCJune 20, 2025 | businesswire.comSee More Headlines BPMC Stock Analysis - Frequently Asked Questions How were Blueprint Medicines' earnings last quarter? Blueprint Medicines Corporation (NASDAQ:BPMC) issued its earnings results on Thursday, May, 1st. The biotechnology company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by $0.32. Blueprint Medicines's revenue for the quarter was up 55.5% compared to the same quarter last year. Read the conference call transcript. When did Blueprint Medicines IPO? Blueprint Medicines (BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Blueprint Medicines' major shareholders? Top institutional investors of Blueprint Medicines include State Street Corp (3.45%), OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC (2.65%), Geode Capital Management LLC (2.39%) and Norges Bank (1.66%). Insiders that own company stock include Kate Haviland, Jeffrey W Albers, Fouad Namouni, Christina Rossi, Tracey L Mccain, Percy H Carter, Michael Landsittel, Debra Durso-Bumpus, Christopher K Murray, Philina Lee, L Becker Hewes and Ariel Hurley. View institutional ownership trends. What other stocks do shareholders of Blueprint Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Blueprint Medicines investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), Humana (HUM), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY). Company Calendar Last Earnings5/01/2025Today9/06/2025Next Earnings (Estimated)10/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BPMC CIK1597264 Webwww.blueprintmedicines.com Phone(617) 374-7580FaxN/AEmployees640Year Founded2011Price Target and Rating Average Price Target for Blueprint Medicines$130.00 High Price Target$135.00 Low Price Target$119.00 Potential Upside/Downside+0.4%Consensus RatingHold Rating Score (0-4)2.11 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)($2.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$67.09 million Net Margins-27.70% Pretax Margin-27.38% Return on Equity-64.60% Return on Assets-17.22% Debt Debt-to-Equity Ratio1.01 Current Ratio2.80 Quick Ratio2.75 Sales & Book Value Annual Sales$562.12 million Price / Sales14.87 Cash FlowN/A Price / Cash FlowN/A Book Value$4.70 per share Price / Book27.54Miscellaneous Outstanding Shares64,582,000Free Float61,863,000Market Cap$8.36 billion OptionableOptionable Beta0.89 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:BPMC) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A Millionaire With SEVEN Clicks? $1,000 in just seven stocks in 2004 could have turned into a million-dolla...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Blueprint Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
